Novel 1,3-dioxolane–coumarin hybrids: From synthesis to pharmacological In Vitro-In Silico profiling
Applied Chemical Engineering · 30.04.2025 · 8 (1)
DOI: 10.59429/ace.v8i1.5651 ↗Kurz gefasst
Fachartikel in der Zeitschrift Applied Chemical Engineering, online erschienen am 30.04.2025. Verfasst von Duha Adnan Hassan und 1 weiteren Autor:innen. Die Arbeit wurde bisher 5-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
In this study, we report the design, synthesis, and comprehensive biological evaluation of a novel series of linear 1,3-dioxolane–coumarin hybrids (DCH1–DCH7) as promising multi-target therapeutic agents. The synthesis involved an optimized multi-step approach beginning with a Pechmann condensation followed by selective esterification reactions, yielding high-purity compounds confirmed via FTIR, 1H-NMR, and 13C-NMR analyses. The hybrids were systematically screened for their antioxidant, anticancer, anti-inflammatory, antidiabetic, and antimicrobial activities. In addition, their biocompatibility was assessed using non-cancerous human cell lines and commensal bacterial strains. Among the synthesized hybrids, DCH4 exhibited remarkable antioxidant and anticancer properties, while DCH1 showed superior anti-inflammatory and antifungal activity. DCH2 demonstrated potent antidiabetic and anti-anaerobic bacterial efficacy, and DCH5 emerged as the most active against aerobic gram-negative bacteria. These bioactivities were closely linked to specific structural modifications, as revealed through structure–activity relationship analyses. In silico evaluations using ProTox-II, PreADME, and SwissADME tools predicted favorable drug-likeness, low toxicity, high oral bioavailability, and acceptable pharmacokinetic profiles, further supporting their therapeutic relevance. Importantly, all hybrids displayed minimal cytotoxic effects on non-cancerous cells and exhibited selective antimicrobial actions, sparing beneficial gut microbiota. This highlights their potential as safer alternatives to conventional therapies. The introduction of the 1,3-dioxolane moiety into the coumarin scaffold contributed significantly to the observed bioactivities, suggesting this hybrid framework as a versatile platform for future drug development. Overall, our findings establish these 1,3-dioxolane–coumarin hybrids as promising multifunctional drug candidates with broad-spectrum pharmacological potential and a strong safety profile, warranting further investigation and development.
Zitieren
APA
Hassan, D. A., & Mustafa, Y. F. (2025). Novel 1,3-dioxolane–coumarin hybrids: From synthesis to pharmacological In Vitro-In Silico profiling. Applied Chemical Engineering, 8(1). https://doi.org/10.59429/ace.v8i1.5651
Vancouver
Hassan DA, Mustafa YF. Novel 1,3-dioxolane–coumarin hybrids: From synthesis to pharmacological In Vitro-In Silico profiling. Applied Chemical Engineering. 2025;8(1). doi:10.59429/ace.v8i1.5651
BibTeX
@article{Hassan2025,
author = {Hassan, Duha Adnan and Mustafa, Yasser Fakri},
title = {Novel 1,3-dioxolane–coumarin hybrids: From synthesis to pharmacological In Vitro-In Silico profiling},
journal = {Applied Chemical Engineering},
year = {2025},
volume = {8},
number = {1},
doi = {10.59429/ace.v8i1.5651}
}
EUVIMED